BioDrugs

ProLynx announces a publication proposing that a long-acting prodrug of SN-38 could be effective in treating Sacituzumab Govitecan-Resistant Tumors

Retrieved on: 
Wednesday, January 24, 2024
Patient, Progression-free survival, ADC, SAN, Half-life, SN-38, FDA, TNBC, BioDrugs, Pharmaceutical industry

In the article the authors inform: “Sacituzumab govitecan (Trodelvy®) is an antibody drug conjugate (ADC) of a humanized anti-TROP2 monoclonal antibody (mAb), linked to SN-38 — the active metabolite of the anti-cancer drug irinotecan and a potent inhibitor of topoisomerase 1.

Key Points: 
  • In the article the authors inform: “Sacituzumab govitecan (Trodelvy®) is an antibody drug conjugate (ADC) of a humanized anti-TROP2 monoclonal antibody (mAb), linked to SN-38 — the active metabolite of the anti-cancer drug irinotecan and a potent inhibitor of topoisomerase 1.
  • Sacituzumab govitecan has been remarkably effective in many clinical trials and is FDA-approved for patients with metastatic triple-negative breast cancer (TNBC) and pre-treated HR+/ HER2- metastatic breast cancer.
  • Hence, sacituzumab govitecan likely acts as a simple prodrug of systemic SN-38 as well as an ADC.
  • The authors posit that a long-acting SN-38, such as ProLynx PLX038, should be an efficacious and less toxic prodrug of systemic SN-38 than sacituzumab govitecan, and could serve as a therapy for certain forms of resistance mechanisms to sacituzumab govitecan.

LEO Pharma to present new data in moderate-to-severe atopic dermatitis and chronic hand eczema at the 31st EADV Congress

Retrieved on: 
Thursday, August 25, 2022
Health, Pharmaceutical, Janus, Tralokinumab, Jake Virtanen, Systematic review, JT, Safety, Pain, Research, Atopic dermatitis, Ageing, Swelling, United Arab Emirates, BioDrugs, Disease, Itch, Autoimmune disease, JAAD, Diagnosis, Science, Poster, HE, Blister, DKK, Annual general meeting, European Academy of Allergy and Clinical Immunology, Immune system, Prevalence, CHE, Thyssen, Adult, AD, Epidemiology, Congress, JAK, Leo Pharma, Journal of the European Academy of Dermatology and Venereology, Patient, Vaccine, Pharmaceutical industry, Medical device, Hospital, Venereology, EU, Veni, vidi, vici, Dermatology

LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world.

Key Points: 
  • LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world.
  • 3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis.
  • Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest.
  • Safety of tralokinumab in paediatric patients aged 12-17 with moderate-to-severe atopic dermatitis: results from the phase 3 ECZTRA 6 trial.

BioAtla Appoints Eric Sievers, M.D., As Chief Medical Officer

Retrieved on: 
Friday, June 28, 2019
Medical specialties, Immunology, Medicine, Monoclonal antibodies, Biotechnology, Immune system, Antibody Solutions, BioDrugs

SAN DIEGO, June 28, 2019 /PRNewswire/ --BioAtla, LLC, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced the appointment of Eric L. Sievers, M.D., as chief medical officer.

Key Points: 
  • SAN DIEGO, June 28, 2019 /PRNewswire/ --BioAtla, LLC, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced the appointment of Eric L. Sievers, M.D., as chief medical officer.
  • Dr. Sievers joins BioAtla with over 25 years of clinical and translational biomedical research experience in multiple settings, including biotechnology industry, hospital- and clinic-based clinical practice and academics.
  • BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and Beijing, China.
  • BioAtla develops novel monoclonal antibody and other protein therapeutic product candidates designed to have more selective targeting, greater efficacy, and more cost-efficient and predictable manufacturing than traditional antibodies.